8-K current report · filed Aug 4, 2026

Bio-rad Laboratories Inc (BIO) 8-K Current Report: August 4, 2026

Item 2.02Item 7.01Item EX-99.1Item 2.05BIO overview

Short answer

Bio-rad Laboratories Inc (BIO) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item 2.05 (Costs Associated with Exit or Disposal Activities). Bio-Rad announced financial results for the quarter ended June 30, 2026.

Bio-rad Laboratories Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Bio-Rad announced financial results for the quarter ended June 30, 2026
  • Supplemental Earnings Presentation referenced under Item 7.01, with detailed results in Exhibit 99.1

Item 2.05 · Costs Associated with Exit or Disposal Activities

  • Strategy-driven restructuring initiated July 31, 2026, targeting global operations and functions
  • Estimated pre-tax charges of approximately $80 million to $90 million, primarily termination benefits and severance
  • Workforce reductions, function consolidations, and facility closures, with international plans subject to consultations
  • Substantial completion expected by fiscal year 2027, with potential for additional charges and cash payments
  • Near-term earnings pressure, with anticipated cost savings and operating improvement as the strategic objective

Item 7.01 · Regulation FD Disclosure

  • Supplemental earnings presentation covers Bio-Rad’s quarter ended June 30, 2026
  • Materials available through Bio-Rad Investor Relations and Exhibit 99.2
  • Presentation provides additional context for investors beyond the core earnings disclosure

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $651.0M, essentially flat year over year; currency-neutral revenue declined 1.9%
  • Life Science revenue $252.0M, down 4.1% reported and 5.1% currency-neutral amid academic research weakness
  • Clinical Diagnostics revenue $399.0M, up 2.6% reported and 0.3% currency-neutral, partially offsetting Life Science pressure
  • Non-GAAP operating margin 12.5% versus 13.6%; non-GAAP EPS $2.62 versus $2.61, while GAAP EPS benefited from investment valuation gains
  • Full-year outlook reaffirmed: non-GAAP currency-neutral revenue decline of approximately 3.0% to growth of 0.5%, operating margin 10.0% to 12.0%

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Bio-rad Laboratories Inc 8-K filings

Get the next BIO 8-K as it lands

Follow BIO for push alerts, or ask the research agent what this filing means.